Convergence Investment Partners, LLC Innoviva, Inc. Transaction History

Convergence Investment Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 22, 2020	SELL	$10.28 - $14.38 $117,716 - $164,665	-11,451 Closed	0 $0
Q3 2019 Oct 22, 2019	SELL	$10.05 - $14.55 $63,134 - $91,403	-6,282 Reduced 35.43%	11,451 $121,000
Q2 2019 Jul 23, 2019	SELL	$13.1 - $14.95 $399,209 - $455,586	-30,474 Reduced 63.21%	17,733 $258,000
Q1 2019 May 01, 2019	SELL	$13.69 - $20.06 $59,825 - $87,662	-4,370 Reduced 8.31%	48,207 $676,000
Q4 2018 Feb 13, 2019	BUY	$13.96 - $18.26 $120,069 - $157,054	8,601 Added 19.56%	52,577 $917,000
Q3 2018 Nov 13, 2018	SELL	$13.63 - $15.7 $752,512 - $866,797	-55,210 Reduced 55.66%	43,976 $670,000
Q2 2018 Aug 07, 2018	SELL	$13.44 - $17.59 $141,765 - $185,539	-10,548 Reduced 9.61%	99,186 $1.37 Million
Q1 2018 May 14, 2018	SELL	$13.8 - $16.99 $282,582 - $347,904	-20,477 Reduced 15.73%	109,734 $1.83 Million
Q4 2017 Jan 16, 2018	BUY	$11.73 - $14.75 $86,215 - $108,412	7,350 Added 5.98%	130,211 $1.85 Million
Q3 2017 Nov 13, 2017	BUY	$12.06 - $14.12 $1.48 Million - $1.73 Million	122,861	122,861 $1.74 Million

240

77M

53.9K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.26B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Convergence Investment Partners, LLC with notifications on news.